The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism

P M Clare1, R A Poorman, L C Kelley

  • 1Department of Cell and Molecular Biology, Pharmacia Corporation, Kalamazoo, Michigan 49007-4940, USA.

Insights

Cyclin-dependent kinases (CDKs) like CDK2 and CDK5 are crucial drug targets. This study reveals both enzymes utilize a sequential random mechanism with anticooperative substrate binding, offering insights for therapeutic development.

Area of Science:

  • Biochemistry
  • Enzymology
  • Molecular Biology

Background:

  • Cyclin-dependent kinases (CDKs) are key regulators of cell cycle and neuronal function.
  • CDK2-cyclin E and CDK5-p25 are implicated in cancer and Alzheimer's disease, respectively.
  • Understanding their kinetic mechanisms is vital for targeted drug development.

Purpose of the Study:

  • To elucidate the kinetic mechanisms of CDK2-cyclin E and CDK5-p25.
  • To characterize substrate binding and enzyme kinetics for these therapeutically relevant kinases.

Main Methods:

  • Enzyme kinetics assays using varying substrate concentrations (peptide and ATP).
  • Inhibition studies with dead-end inhibitors, including PNU 112455A.
  • Kinetic data analysis using nonlinear least squares and Lineweaver-Burk methods.
  • X-ray crystallography to determine inhibitor binding mode.

Main Results:

  • Both CDK2-cyclin E and CDK5-p25 were determined to follow a sequential random kinetic mechanism.
  • Substrate binding was characterized by anticooperativity, where initial substrate binding reduces affinity for the second.
  • Kinetic parameters (Km, anticooperativity factor alpha) were quantified for both enzyme systems.

Conclusions:

  • The sequential random mechanism and anticooperative substrate binding are conserved features of CDK2-cyclin E and CDK5-p25.
  • This mechanistic understanding provides a foundation for designing specific inhibitors for oncology and neurodegenerative diseases.

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...